IL118836A - Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan - Google Patents
Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindanInfo
- Publication number
- IL118836A IL118836A IL11883696A IL11883696A IL118836A IL 118836 A IL118836 A IL 118836A IL 11883696 A IL11883696 A IL 11883696A IL 11883696 A IL11883696 A IL 11883696A IL 118836 A IL118836 A IL 118836A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical compositions
- aminoindan
- disease
- propargyl
- injury
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL11883696A IL118836A (en) | 1996-07-11 | 1996-07-11 | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
DE69736066T DE69736066T2 (de) | 1996-07-11 | 1997-06-20 | Pharmazeutische zusammensetzungen enthaltend s-(-)-n-propargyl-1-aminoindan |
PCT/IL1997/000205 WO1998002152A1 (en) | 1996-07-11 | 1997-06-20 | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan |
CNB971971994A CN1149985C (zh) | 1996-07-11 | 1997-06-20 | 含s-(-)-n-炔丙基-1-氨基茚满的药物组合物 |
EP97927353A EP0929298B1 (en) | 1996-07-11 | 1997-06-20 | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan |
CA002260037A CA2260037C (en) | 1996-07-11 | 1997-06-20 | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
JP50580698A JP4368421B2 (ja) | 1996-07-11 | 1997-06-20 | S―(―)―n―プロパルギル―1―アミノインダンを含む医薬組成物 |
AU31880/97A AU3188097A (en) | 1996-07-11 | 1997-06-20 | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan |
AT97927353T ATE328590T1 (de) | 1996-07-11 | 1997-06-20 | Pharmazeutische zusammensetzungen enthaltend s-(- )-n-propargyl-1-aminoindan |
HU9904525A HU226961B1 (en) | 1996-07-11 | 1997-06-20 | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan |
NO19990088A NO326052B1 (no) | 1996-07-11 | 1999-01-08 | Anvendelse av S-(-)-N-propargyl-1-aminoindamin eller et farmasoytisk akseptabelt salt derav for fremstilling av et medikament (a) for behandling av neurotrauma eller (b) for forbedring av hukommelsen hos en post-CHI-pasient. |
US09/228,153 US6277886B1 (en) | 1996-07-11 | 1999-01-11 | Pharmaceutical compositions comprising S-(−)-N-propargyl-1-aminoindan |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL11883696A IL118836A (en) | 1996-07-11 | 1996-07-11 | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
Publications (2)
Publication Number | Publication Date |
---|---|
IL118836A0 IL118836A0 (en) | 1996-10-31 |
IL118836A true IL118836A (en) | 2001-01-11 |
Family
ID=11069065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL11883696A IL118836A (en) | 1996-07-11 | 1996-07-11 | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
Country Status (12)
Country | Link |
---|---|
US (1) | US6277886B1 (xx) |
EP (1) | EP0929298B1 (xx) |
JP (1) | JP4368421B2 (xx) |
CN (1) | CN1149985C (xx) |
AT (1) | ATE328590T1 (xx) |
AU (1) | AU3188097A (xx) |
CA (1) | CA2260037C (xx) |
DE (1) | DE69736066T2 (xx) |
HU (1) | HU226961B1 (xx) |
IL (1) | IL118836A (xx) |
NO (1) | NO326052B1 (xx) |
WO (1) | WO1998002152A1 (xx) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
EP2135611A1 (en) | 2001-03-01 | 2009-12-23 | Hollis-Eden Pharmaceuticals Inc. | Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy |
KR20050057086A (ko) | 2002-08-28 | 2005-06-16 | 홀리스-에덴 파마슈티칼즈, 인코포레이티드 | 치료적 처치 방법 |
AU2003282337B2 (en) * | 2002-11-07 | 2009-07-16 | Technion Research And Development Foundation Ltd. | Neuroprotective iron chelators and pharmaceutical compositions comprising them |
WO2004045515A2 (en) | 2002-11-15 | 2004-06-03 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis |
EP1686973A4 (en) | 2003-11-25 | 2009-03-25 | Technion Res & Dev Foundation | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISEASES |
US8097608B2 (en) * | 2003-11-25 | 2012-01-17 | Technion Research And Development Foundation Ltd. | Methods for treatment of cardiovascular disorders and diseases |
JP2005232148A (ja) * | 2004-02-03 | 2005-09-02 | Technion Research & Development Foundation Ltd | 神経保護剤としてプロパルギルアミンの使用 |
AU2005269416B2 (en) * | 2004-07-26 | 2011-07-28 | Teva Pharmaceutical Industries, Ltd. | Pharmaceutical dosage forms including rasagiline |
US20060025446A1 (en) * | 2004-07-27 | 2006-02-02 | Jeffrey Sterling | Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders |
US20070014719A1 (en) | 2004-09-29 | 2007-01-18 | Reading Christopher L | Steroid analogs and characterization and treatment methods |
SI1848415T1 (sl) * | 2005-02-17 | 2013-08-30 | Teva Pharmaceutical Industries Ltd. | Kombinacijska terapija z glatiramer acetatom in razagilinom za zdravljenje muliple skleroze |
KR20140103356A (ko) | 2005-02-23 | 2014-08-26 | 테바 파마슈티컬 인더스트리즈 리미티드 | 함량 균일성이 개선된 라사길린 제형 |
US8263655B2 (en) * | 2005-10-06 | 2012-09-11 | Technion Research And Development Foundation Ltd | Methods for treatment of renal failure |
JP2009521402A (ja) * | 2005-11-17 | 2009-06-04 | テバ ファーマシューティカル インダストリーズ リミティド | プロパルギル化アミノインダンの分離のための方法 |
US7572834B1 (en) | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
EP1956904B1 (en) | 2005-12-09 | 2017-04-12 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Low-dose ladostigil for the treatment of mild cognitive impairment |
ES2551481T3 (es) | 2006-02-21 | 2015-11-19 | Teva Pharmaceutical Industries, Ltd. | Uso de rasagilina para el tratamiento de atrofia multisistémica |
TW200744576A (en) | 2006-02-24 | 2007-12-16 | Teva Pharma | Propargylated aminoindans, processes for preparation, and uses thereof |
EP2007369A4 (en) | 2006-04-03 | 2009-07-01 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST |
EP1892233A1 (de) * | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
ZA200903903B (en) * | 2006-12-14 | 2010-08-25 | Teva Pharma | Crystalline solid rasagiline base |
WO2008076315A1 (en) * | 2006-12-14 | 2008-06-26 | Teva Pharmaceutical Industries, Ltd. | Tannate salt of rasagiline |
EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
US20090062400A1 (en) * | 2007-09-05 | 2009-03-05 | Laurence Oron | Method of treating glaucoma using rasagiline |
US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
CN101909438A (zh) * | 2008-01-11 | 2010-12-08 | 泰华制药工业有限公司 | 雷沙吉兰制剂、其制备及用途 |
WO2009122351A2 (en) * | 2008-04-01 | 2009-10-08 | Kangwon National University | Anti-parkinsonian compounds mppe |
AU2009258120B2 (en) * | 2008-06-10 | 2014-11-27 | Teva Pharmaceutical Industries, Ltd. | Rasagiline soft gelatin capsules |
BRPI0909894A2 (pt) * | 2008-06-13 | 2015-07-28 | Teva Pharma | "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica. |
WO2009154777A2 (en) | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries, Ltd. | Process for preparing and drying solid rasagiline base |
JP2011525489A (ja) * | 2008-06-19 | 2011-09-22 | テバ ファーマシューティカル インダストリーズ リミティド | ラサリジン塩基の精製方法 |
US8080584B2 (en) * | 2009-01-23 | 2011-12-20 | Teva Pharmaceuticals Industries, Ltd. | Delayed release rasagiline citrate formulation |
RS53504B1 (en) | 2009-07-09 | 2015-02-27 | Ratiopharm Gmbh | RAZAGILIN SALTS AND THEIR PHARMACEUTICAL PREPARATIONS |
AU2011212068B2 (en) | 2010-02-03 | 2016-08-18 | Pharma Two B Ltd. | Extended release formulations of rasagiline and uses thereof |
WO2012015946A1 (en) | 2010-07-27 | 2012-02-02 | Teva Pharmaceutical Industries Ltd. | Dispersion of rasagiline citrate |
EP2603212A4 (en) | 2010-07-27 | 2014-01-08 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF SMOKING DISORDER |
US9346746B2 (en) | 2011-10-10 | 2016-05-24 | Teva Pharmaceutical Industries, Ltd. | R(+)-N-formyl-propargyl-aminoindan |
CA2851433A1 (en) | 2011-10-10 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | R(+)-n-methyl-propargyl-aminoindan |
CA2882072A1 (en) | 2012-08-17 | 2014-02-20 | Teva Pharmaceutical Industries Ltd. | Parenteral formulations of rasagiline |
CN104177611A (zh) * | 2013-05-27 | 2014-12-03 | 韩文毅 | 一种非线性的聚合物及其制备和用途 |
CN104177610A (zh) * | 2013-05-27 | 2014-12-03 | 韩文毅 | 一种非线性的聚合物及其制备和用途 |
CN111333517A (zh) * | 2018-12-19 | 2020-06-26 | 上海奥博生物医药技术有限公司 | 一种制备雷沙吉兰的改进方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1187017A (en) * | 1966-07-16 | 1970-04-08 | Aspro Nicholas Ltd | Substituted 1-Amino Indanes and Tetrahydronaphthalens |
US5744500A (en) * | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
IL92952A (en) * | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
IL112819A (en) * | 1991-10-16 | 2001-11-25 | Teva Pharma | Fluorinated 1-aminoindan compounds and a process for their preparation |
IL111240A (en) * | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
ATE346598T1 (de) * | 1994-01-10 | 2006-12-15 | Teva Pharma | 1-aminoindanderivate und zusammensetzungen hiervon |
IL115357A (en) * | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
-
1996
- 1996-07-11 IL IL11883696A patent/IL118836A/xx not_active IP Right Cessation
-
1997
- 1997-06-20 CA CA002260037A patent/CA2260037C/en not_active Expired - Lifetime
- 1997-06-20 DE DE69736066T patent/DE69736066T2/de not_active Expired - Lifetime
- 1997-06-20 AT AT97927353T patent/ATE328590T1/de not_active IP Right Cessation
- 1997-06-20 WO PCT/IL1997/000205 patent/WO1998002152A1/en active IP Right Grant
- 1997-06-20 CN CNB971971994A patent/CN1149985C/zh not_active Expired - Lifetime
- 1997-06-20 JP JP50580698A patent/JP4368421B2/ja not_active Expired - Lifetime
- 1997-06-20 AU AU31880/97A patent/AU3188097A/en not_active Abandoned
- 1997-06-20 EP EP97927353A patent/EP0929298B1/en not_active Expired - Lifetime
- 1997-06-20 HU HU9904525A patent/HU226961B1/hu unknown
-
1999
- 1999-01-08 NO NO19990088A patent/NO326052B1/no not_active IP Right Cessation
- 1999-01-11 US US09/228,153 patent/US6277886B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US6277886B1 (en) | 2001-08-21 |
NO990088D0 (no) | 1999-01-08 |
NO326052B1 (no) | 2008-09-08 |
AU3188097A (en) | 1998-02-09 |
HUP9904525A2 (hu) | 2000-11-28 |
HU226961B1 (en) | 2010-03-29 |
CN1227486A (zh) | 1999-09-01 |
JP2000514453A (ja) | 2000-10-31 |
CA2260037A1 (en) | 1998-01-22 |
EP0929298B1 (en) | 2006-06-07 |
IL118836A0 (en) | 1996-10-31 |
DE69736066D1 (de) | 2006-07-20 |
CN1149985C (zh) | 2004-05-19 |
EP0929298A1 (en) | 1999-07-21 |
HUP9904525A3 (en) | 2000-12-28 |
ATE328590T1 (de) | 2006-06-15 |
WO1998002152A1 (en) | 1998-01-22 |
JP4368421B2 (ja) | 2009-11-18 |
NO990088L (no) | 1999-03-10 |
DE69736066T2 (de) | 2006-12-28 |
CA2260037C (en) | 2007-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL118836A (en) | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan | |
HU913447D0 (en) | Medical preparations and their use in treating neurologic disorders | |
WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
NL300205I1 (nl) | N-enentiomeer van N-propargyl-1-aminoindaan voor de behandeling van verschillende ziekten, en mesylaat, esylaat en sulfaat daarvan. | |
UA41906C2 (uk) | Спосіб лікування неврологічних порушень, викликаних травмами | |
MX9708977A (es) | Uso de r-enantiomero de sales de n-propargilo-1-aminoindano, y composiciones de las mismas. | |
CA2114251A1 (en) | Igf-1 to improve the neural condition | |
AU2001273574A1 (en) | Substituted 5-alkynyl pyrimidines having neurotrophic activity | |
MY130145A (en) | Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders. | |
WO1999045011A8 (en) | Glycine transport inhibitors | |
CA2148194A1 (en) | Cyclopeptides of the formula i | |
MY118526A (en) | Method for improving the pharmacokinetics of tipranavir | |
CA2122058A1 (en) | Tgf-beta to improve neural outcome | |
CA2143610A1 (en) | Use of norastemizole for the treatment of allergic disorders | |
CA2139385A1 (en) | Products containing g-csf and tnf binding protein | |
CA2374997A1 (en) | Il6ril6 chimera for the treatment of neurodegenerative diseases | |
MXPA01009384A (es) | Composiciones farmaceuticas que comprenden un derivado de pirimidina y ciclodextrina. | |
CA2135752A1 (en) | Use of (E)-2-(p-Fluorophenethyl)-3-Fluoroallylamine in the Treatment of Alzheimer's Disease | |
NZ268039A (en) | Use of efaroxan in treating parkinson's disease | |
DE69330809T2 (de) | Therapeutisches Agens für Neutropenie | |
CA2154485A1 (en) | Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders | |
IT1264428B1 (it) | Composizioni farmaceutiche per il trattamento della psoriasi | |
EP1712231A3 (en) | Method for improving the pharmacokinetics of tipranavir |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees | ||
NE | Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967) | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
EXP | Patent expired |